1362.1 - Resubmission Cetuximab and RAS testing under MBS 73330

Page last updated: 21 June 2019

Application Detail



Description of Medical Service

Cetuximab is used to treat patients with metastatic colorectal cancer (CRC). Cetuximab is a personalised medicine tailored to the genetic make-up of a patient. A patient’s cancer cells must therefore be tested to see if they contain the normal (“wild-type”) or a mutant form of a gene called RAS. Cetuximab is only used to treat metastatic CRC patients who have a normal RAS gene.

Description of Medical Condition

Colorectal cancer, commonly known as colon or bowel cancer, is a cancer formed by uncontrolled cell growth in the colon or rectum (parts of the large intestine), or in the appendix. Symptoms of colorectal cancer typically include rectal bleeding and anemia, sometimes associated with weight loss and changes in bowel habits. Metastatic cancer is cancer that has spread from the place where it first started to other place(s) in the body. The symptoms and signs of metastatic colorectal cancer depend on the location of the tumour in the bowel and on where it has spread elsewhere in the body.

Reason for Application

Amendment to MBS item

Medical Service Type


Previous Application Number


Associated Documentation

Application Form


PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document 3 Oct 2014 (PDF 86 KB)
Public Summary Document 3 October 2014 (Word 106 KB)

Predicted versus Actual

Public Summary Document - July 2018 (PDF 1252 KB)
Public Summary Document - July 2018 (Word 133 KB)

Meetings for this Application






3 October 2014
27 July 2018